CHEK1 and neoplasm: However, there was no appreciable change in phosphorylation of CHK1 at Ser345 in the AZD1775 monotherapy and combination treatment groups compared with the vehicle treatment groups in the AT3 tumours (lower band indicated by the arrow in Supplementary Fig. 2d).